DD150545A5 - Verfahren zur herstellung eines arzneipraeparates zur behandlung von carcinomen - Google Patents

Verfahren zur herstellung eines arzneipraeparates zur behandlung von carcinomen Download PDF

Info

Publication number: DD150545A5
Authority: DD; German Democratic Republic
Prior art keywords: cells; cytostatic; treatment; carcinoma cells; carcinoma
Prior art date: 1979-05-10

Application number

DD80221015A

Other languages

German (de)

English (en)

Inventor

Hans Limburg

Original Assignee

Hans Limburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-05-10

Filing date

1980-05-09

Publication date

1981-09-09

1980-05-09 Application filed by Hans Limburg filed Critical Hans Limburg

1981-09-09 Publication of DD150545A5 publication Critical patent/DD150545A5/de

Links

238000011282 treatment Methods 0.000 title claims abstract description 37
239000003814 drug Substances 0.000 title abstract description 8
229940079593 drug Drugs 0.000 title abstract description 7
238000004519 manufacturing process Methods 0.000 title description 3
239000000824 cytostatic agent Substances 0.000 claims abstract description 40
206010028980 Neoplasm Diseases 0.000 claims abstract description 38
201000009030 Carcinoma Diseases 0.000 claims abstract description 35
230000001085 cytostatic effect Effects 0.000 claims abstract description 35
238000002360 preparation method Methods 0.000 claims abstract description 35
238000012360 testing method Methods 0.000 claims abstract description 17
230000002238 attenuated effect Effects 0.000 claims abstract description 11
238000004113 cell culture Methods 0.000 claims abstract description 10
230000035945 sensitivity Effects 0.000 claims abstract description 10
238000000034 method Methods 0.000 claims description 24
235000015097 nutrients Nutrition 0.000 claims description 11
238000011534 incubation Methods 0.000 claims description 10
230000008569 process Effects 0.000 claims description 9
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
238000012258 culturing Methods 0.000 claims 1
206010016256 fatigue Diseases 0.000 claims 1
210000004027 cell Anatomy 0.000 description 67
239000000243 solution Substances 0.000 description 30
239000006285 cell suspension Substances 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
210000001519 tissue Anatomy 0.000 description 15
201000011510 cancer Diseases 0.000 description 14
239000011550 stock solution Substances 0.000 description 13
239000002609 medium Substances 0.000 description 12
238000002560 therapeutic procedure Methods 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
206010033128 Ovarian cancer Diseases 0.000 description 7
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
210000000481 breast Anatomy 0.000 description 5
244000309466 calf Species 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 5
229960004528 vincristine Drugs 0.000 description 5
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 5
NOVZFMNCTCKLPF-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OCCC)=C(N2CC2)C(=O)C(OCCC)=C1N1CC1 NOVZFMNCTCKLPF-UHFFFAOYSA-N 0.000 description 4
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
CPTIBDHUFVHUJK-NZYDNVMFSA-N mitopodozide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 4
229950010088 mitopodozide Drugs 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
229960001322 trypsin Drugs 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
235000013343 vitamin Nutrition 0.000 description 4
239000011782 vitamin Substances 0.000 description 4
229940088594 vitamin Drugs 0.000 description 4
229930003231 vitamin Natural products 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
210000001015 abdomen Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
230000000877 morphologic effect Effects 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
229960003531 phenolsulfonphthalein Drugs 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000002504 physiological saline solution Substances 0.000 description 3
239000013049 sediment Substances 0.000 description 3
235000011121 sodium hydroxide Nutrition 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
238000005406 washing Methods 0.000 description 3
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
206010027476 Metastases Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000012984 antibiotic solution Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
238000002513 implantation Methods 0.000 description 2
210000001165 lymph node Anatomy 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
239000000203 mixture Substances 0.000 description 2
210000003200 peritoneal cavity Anatomy 0.000 description 2
210000004303 peritoneum Anatomy 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
150000003722 vitamin derivatives Chemical class 0.000 description 2
208000006678 Abdominal Neoplasms Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000238017 Astacoidea Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
206010014733 Endometrial cancer Diseases 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
206010059282 Metastases to central nervous system Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
239000002253 acid Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
210000001099 axilla Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
NSJYMFYVNWVGON-UHFFFAOYSA-N glisentide Chemical compound COC1=CC=CC=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCC2)C=C1 NSJYMFYVNWVGON-UHFFFAOYSA-N 0.000 description 1
229950008402 glisentide Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
238000009607 mammography Methods 0.000 description 1
239000010445 mica Substances 0.000 description 1
229910052618 mica group Inorganic materials 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000007468 re-laparotomy Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000002633 shock therapy Methods 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
206010041823 squamous cell carcinoma Diseases 0.000 description 1
230000003068 static effect Effects 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000001931 thermography Methods 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
231100000925 very toxic Toxicity 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1
229940072358 xylocaine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Oncology (AREA)
Mycology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Virology (AREA)
Microbiology (AREA)
Developmental Biology & Embryology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DD80221015A 1979-05-10 1980-05-09 Verfahren zur herstellung eines arzneipraeparates zur behandlung von carcinomen DD150545A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19792918927 DE2918927A1 (de)	1979-05-10	1979-05-10	Arzneipraeparat zur behandlung von carcinomen und verfahren zu dessen herstellung

Publications (1)

Publication Number	Publication Date
DD150545A5 true DD150545A5 (de)	1981-09-09

Family

ID=6070441

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD80221015A DD150545A5 (de)	1979-05-10	1980-05-09	Verfahren zur herstellung eines arzneipraeparates zur behandlung von carcinomen

Country Status (20)

Country	Link
EP (1)	EP0019167B1 (el)
JP (1)	JPS55151515A (el)
AT (1)	AT369653B (el)
AU (1)	AU5806980A (el)
CA (1)	CA1139219A (el)
CH (1)	CH647152A5 (el)
DD (1)	DD150545A5 (el)
DE (2)	DE2918927A1 (el)
DK (1)	DK189580A (el)
ES (1)	ES8200228A1 (el)
FI (1)	FI801420A (el)
FR (1)	FR2455891A1 (el)
GB (1)	GB2048069B (el)
GR (1)	GR68513B (el)
IL (1)	IL59833A0 (el)
IT (1)	IT1133086B (el)
NO (1)	NO801388L (el)
PL (1)	PL224116A1 (el)
PT (1)	PT71195B (el)
ZA (1)	ZA802391B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3432714A1 (de) *	1984-09-06	1986-04-24	Behringwerke Ag, 3550 Marburg	Tumortherapeutikum und verfahren zu seiner herstellung
DE3806565A1 (de) *	1988-03-01	1989-09-14	Deutsches Krebsforsch	Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
WO1992010198A1 (en) *	1990-12-06	1992-06-25	Johnson & Johnson Research Pty Limited	Immunotherapeutic agents, compositions and methods
SE9604581D0 (sv) *	1996-12-12	1996-12-12	Karolinska Innovations Ab	An agent against cancer and virus infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2024458A1 (en) *	1970-05-20	1971-12-02	Hartmann geb. Ungewitter, Philippine, Dr., 8000 München	Tumour antigen - modified and potentiated by irradiation
DE2643215A1 (de) *	1976-09-25	1978-04-06	Bayer Ag	Cancerostatisch wirksame praeparationen aus tumorzellen und ein verfahren zu ihrer herstellung
DE2802277A1 (de) *	1978-01-19	1979-08-02	Jaeger Karl Heinz Dr Med	Verfahren zur herstellung eines gegen boesartiges wachstum gerichteten immunologischen wirkstoffkomplexes aus zellen

1979
- 1979-05-10 DE DE19792918927 patent/DE2918927A1/de not_active Withdrawn
1980
- 1980-04-15 GB GB8012348A patent/GB2048069B/en not_active Expired
- 1980-04-15 IL IL59833A patent/IL59833A0/xx unknown
- 1980-04-21 ZA ZA00802391A patent/ZA802391B/xx unknown
- 1980-04-28 CA CA000350795A patent/CA1139219A/en not_active Expired
- 1980-04-30 DK DK189580A patent/DK189580A/da unknown
- 1980-05-02 DE DE8080102400T patent/DE3065252D1/de not_active Expired
- 1980-05-02 EP EP80102400A patent/EP0019167B1/de not_active Expired
- 1980-05-02 GR GR61842A patent/GR68513B/el unknown
- 1980-05-02 FI FI801420A patent/FI801420A/fi not_active Application Discontinuation
- 1980-05-05 AU AU58069/80A patent/AU5806980A/en not_active Abandoned
- 1980-05-06 AT AT0240280A patent/AT369653B/de not_active IP Right Cessation
- 1980-05-06 CH CH3510/80A patent/CH647152A5/de not_active IP Right Cessation
- 1980-05-07 PT PT71195A patent/PT71195B/pt unknown
- 1980-05-08 PL PL22411680A patent/PL224116A1/xx unknown
- 1980-05-09 FR FR8010400A patent/FR2455891A1/fr active Granted
- 1980-05-09 NO NO801388A patent/NO801388L/no unknown
- 1980-05-09 JP JP6082680A patent/JPS55151515A/ja active Pending
- 1980-05-09 ES ES491356A patent/ES8200228A1/es not_active Expired
- 1980-05-09 IT IT67731/80A patent/IT1133086B/it active
- 1980-05-09 DD DD80221015A patent/DD150545A5/de unknown

Also Published As

Publication number	Publication date
IT8067731A0 (it)	1980-05-09
AU5806980A (en)	1980-11-13
EP0019167B1 (de)	1983-10-12
IT1133086B (it)	1986-07-09
FR2455891B1 (el)	1983-12-30
NO801388L (no)	1980-11-11
ATA240280A (de)	1982-06-15
CA1139219A (en)	1983-01-11
GB2048069B (en)	1983-05-25
IL59833A0 (en)	1980-06-30
GR68513B (el)	1982-01-11
CH647152A5 (de)	1985-01-15
AT369653B (de)	1983-01-25
EP0019167A3 (en)	1981-09-09
DK189580A (da)	1980-11-11
PL224116A1 (el)	1981-07-10
GB2048069A (en)	1980-12-10
ES491356A0 (es)	1981-11-16
PT71195B (en)	1981-09-17
JPS55151515A (en)	1980-11-26
ES8200228A1 (es)	1981-11-16
EP0019167A2 (de)	1980-11-26
FR2455891A1 (fr)	1980-12-05
DE2918927A1 (de)	1980-11-20
ZA802391B (en)	1981-04-29
PT71195A (en)	1980-06-01
FI801420A (fi)	1980-11-11
DE3065252D1 (en)	1983-11-17

Publication	Publication Date	Title
Rous et al.	1914	On the causation by filterable agents of three distinct chicken tumors
DE4204012A1 (de)	1993-08-19	Mitogenfreie substanz, deren herstellung und verwendung
DE19904785A1 (de)	2000-08-10	Verfahren zur Herstellung von stabilem Alginatmaterial
DE60214029T2 (de)	2007-03-29	Milchsäurebakterien und deren verwendungen zur behandlung von und vorbeugung gegen krebs
DE69725317T2 (de)	2004-07-29	Implantierbare agarose-kollagenkügelchen enthaltende zellen, die ein diffusionsfähiges biologisches produkt bilden und ihre verwendung
Ludford	1929	The vital staining of normal and malignant cells.-II. The staining of malignant tumours with trypan blue
DE3104815C2 (de)	1983-07-07	Verfahren zur Herstellung eines Verbundstoffs mit Langzeit-Freigabe
DE69425707T2 (de)	2000-12-28	Medien für die isolierung und stabilisierung von zellen
DD150545A5 (de)	1981-09-09	Verfahren zur herstellung eines arzneipraeparates zur behandlung von carcinomen
Fagerholm et al.	1986	Human and experimental lens repair and calcification
DE19961141A1 (de)	2001-07-26	Pharmazeutische Zusammensetzung aus Spinnengiften sowie deren Herstellung und Verwendung zur Behandlung von Tumorerkrankungen
Alexander et al.	1971	Stimulants of cellular proliferation in wounds
DE1951822A1 (de)	1971-04-22	Pharmazeutisches Praeparat zur Behandlung von Krebs
EP1881838B1 (en)	2012-07-18	Antitumor agent on the base of bcg vaccine, method for its preparation and its use
DE3236298C2 (el)	1987-09-24
DE3524794A1 (de)	1986-01-16	Pharmazeutisches praeparat enthaltend lebende vermehrungsfaehige embryonalzellen, verfahren zu dessen herstellung und testverfahren zur bestimmung der pharmazeutischen wirksamkeit
Faber	1893	The part played by giant cells in phagocytosis
DE69825433T2 (de)	2005-09-15	Aktive substanz für inhibierung von tumoröse proliferation im geweben aus der ektoderm
DE2518509B2 (de)	1980-06-04	Pharmazeutisches Mittel für Antitumoraktivität, enthaltend Abrin
Lumb	1951	Chromaffin tumour with chronic hypertension
DE102018113041A1 (de)	2019-01-24	Implantierbares pharmazeutisches Erzeugnis
Hennekeuser et al.	1970	Klinische, histologische und cytogenetische Befunde bei Patienten mit Thorotrastschaden
DE4244894C2 (de)	1998-04-16	Vakzine für eine Immuntherapie sowie Verfahren zu deren Herstellung
DE681344C (de)	1939-09-21	Verfahren zum Aufschliessen und Aufloesen von Bakterien, Viren und anderen Mikroorganismen, wie Protozoen, Spirochaeten u. dgl., und Hyphomyzeten, Blastomyzeten u. dgl.
McNee	1920	Cholesterin Metabolism: An Account of Physiological, Pathological and Experimental Investigations